NCT06541262 2026-03-02
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT06709495 2026-02-19
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT01871766 2025-12-17
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT06023641 2025-08-19
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT06721689 2025-03-26
PEEL-224
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT04625907 2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2 Recruiting
NCT01355445 2019-09-18
VIT-0910
Centre Oscar Lambret
Phase 2 Completed
NCT00162695 2005-09-13
Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Terminated